How a pancreatic cancer biopsy is done — EUS-FNA, core needle, and when it is skipped

A scan can show a mass in the pancreas, describe its size, and say what it is touching. It cannot say what the cells are. That is the whole job of a pancreatic cancer biopsy: a small sample of tissue or cells is taken from the mass so that a pathologist can look at it under a microscope and name it. Until that happens, what you have is a suspicion supported by imaging, not a diagnosis.

Two separate questions get decided before anyone picks up a needle, and they are often run together in conversation, which is why people leave clinic confused. The first is whether tissue is needed at all before treatment starts. The second, if it is, is which route the sample should be taken by. Neither answer is automatic, and both depend on what the plan is likely to be afterwards.

The route matters more than most people are told. A sample can be taken from inside the gut wall with an endoscope, using endoscopic ultrasound with fine-needle aspiration or core biopsy, or from outside, with a needle passed through the abdominal wall under CT or ultrasound guidance. For a mass that might still be removable by surgery, the endoscopic route is generally preferred, because the needle track it creates lies within the tissue that the operation would take out anyway. A percutaneous needle crosses the abdominal cavity to get there, and that raises a theoretical concern about seeding tumour cells along the track in someone who is heading for an operation with the intention of cure.

There is also a situation people find genuinely surprising: sometimes the right answer is no biopsy before surgery. If a scan shows a clearly removable mass with all the features of a pancreatic cancer, and the plan is to operate straight away, waiting for tissue can delay the operation without changing it, because a negative or unclear sample would not stop the surgeon proceeding. In that setting the diagnosis is confirmed on the specimen after it is removed. Where treatment starts with chemotherapy instead, or where the disease has spread, tissue is required first — you cannot give systemic treatment on the strength of a picture.

One thing to be plain about from the outset. CION does not perform biopsy procedures in-house. Every route by which pancreatic tissue is obtained — endoscopic, percutaneous, at ERCP or at operation — is coordinated with specialist gastroenterology, endoscopy, interventional radiology and surgical partners, carried out at their unit, and that part of your care may be billed there. What CION runs directly, across 35+ centres, is the decision about whether tissue is needed and by which route, the scans and bloods that inform it, the reading of the result at tumour board, and every arm of treatment that follows. If you want the wider picture first, start with our complete guide to pancreatic cancer.

• Is surgery still on the table for me? The answer drives the route. If an operation with the intention of cure is still possible, ask specifically why a percutaneous needle is being proposed instead of an endoscopic one.
• Will the result actually change what happens next? If the plan is an upfront operation whatever the sample shows, a biopsy first may only add delay.
• Which needle, and will a core be taken? Cells confirm the diagnosis; a core sample gives the pathologist more to work with for typing and for any molecular testing later.
• Is enough material being taken for genetic and molecular work? Worth raising before the procedure, not after, because a second biopsy purely to obtain more tissue is an avoidable ordeal.
• What happens if the sample is non-diagnostic? It is a recognised outcome, not a mistake. Ask what the plan is — repeat sampling, a different route, or proceeding on imaging alone.
• Who reads the report, and when do I see them? A pathology report is not self-explanatory; understanding your pancreatic cancer pathology report sets out what each line means.
• Which parts are billed where? The sampling is done at a partner unit. Ask for the split between that unit and your oncology team in writing, before the date is booked.

1. 1

   The decision is made at CION

   Your oncologist looks at the pancreatic-protocol CT, any MRI, your bloods and CA 19-9, and works out whether tissue is needed before treatment starts and which route makes sense. If a biopsy would only delay an operation without changing it, we will say so.

   In-house at CION
2. 2

   The procedure is booked at a partner unit

   Endoscopic sampling needs an endoscopy suite and an operator who does it regularly; a percutaneous biopsy needs an interventional radiology list. CION runs neither, and we would rather tell you that than blur it. We arrange the appointment, and that part of your care is billed by the partner unit.

   Coordinated with endoscopy and radiology partners
3. 3

   Preparation is confirmed with you

   Fasting from the night before for a sedated endoscopic procedure, and a clear instruction about blood thinners, which usually need pausing beforehand. Diabetes medication timing is adjusted. Someone should come with you and take you home afterwards.

   Coordinated with the partner unit
4. 4

   The day itself

   For an endoscopic sampling you are sedated and remember little of it. The imaging and needle passes take under an hour in most cases, then a few hours of observation. There is no cut and no stitches. A percutaneous biopsy is done awake with local anaesthetic and is shorter still. Most people go home the same day.

   Coordinated with the partner unit
5. 5

   The laboratory work, which is the slow part

   The sample is processed, stained and often stained again with additional markers to settle the type. That is why a report usually takes several working days rather than arriving the next morning. Rushing it produces a vaguer answer, not a faster one.

   Coordinated with the partner laboratory
6. 6

   The result comes back to your oncologist and to tumour board

   We read the pathology against your imaging rather than in isolation, take the case to a board where medical, surgical and radiation oncologists look at it together, and then explain to you in person what it says, what it changes and what happens next.

   In-house at CION

This matters practically, because it decides where you travel and who invoices you. CION does not perform pancreatic biopsies. Endoscopic ultrasound with fine-needle aspiration or core biopsy, percutaneous image-guided biopsy, sampling at ERCP, staging laparoscopy and all pancreatic surgery are coordinated with specialist gastroenterology, endoscopy, interventional radiology and hepatobiliary surgical partners, and those parts of your care may be billed by them rather than by us. The same is true of biliary and duodenal stenting, coeliac plexus block, PET-CT and DOTATATE PET, and receptor-targeted radionuclide therapy.

What happens at CION is everything on either side of the procedure, and on this pathway that is almost all of it. The decision about whether tissue is needed and by which route. The pancreatic-protocol CT, the MRI and MRCP, CA 19-9 and routine bloods, ordered and reported in-house across 35+ centres. The tumour board that reads the pathology alongside the imaging. Then treatment itself: chemotherapy before or after surgery and in advanced disease, maintenance treatment where an inherited repair-gene fault is found, immune-based treatment where the tissue shows defective mismatch repair, systemic therapy for neuroendocrine tumours, radiation, chemoradiation and SBRT. Alongside that, genetic counselling, nutrition and pancreatic enzyme support, pain and psycho-oncology care, and long-term follow-up.

The first appointment is a free 45-minute consultation, which is long enough to open your scans in front of you, say plainly whether a biopsy is the right next step, and write down the sequence rather than leaving you to piece it together between departments.

• Your scans read with you, not summarised back at you from a report — bring the discs as well as the printed pages.
• A straight answer on whether tissue is needed before treatment, or whether it would only delay an operation that is going ahead anyway.
• The biopsy arranged for you at a partner unit, with the route chosen deliberately rather than by whatever list has space.
• A written split of what the partner unit bills and what CION bills, before anything is booked.
• Aarogyasri, NTR Vaidya Seva and insurance routes checked against each part of the pathway, not only the treatment.
• The result explained in person, with the treatment options set out in pancreatic cancer treatment in Hyderabad.

Medical disclaimer: This page explains how a tissue sample is obtained in suspected pancreatic cancer and how the routes differ, and is reviewed by a CION medical oncologist with reference to NCCN guidance on pancreatic adenocarcinoma and the World Health Organization classification of neuroendocrine neoplasms. It is general information and not advice about your own procedure; whether a biopsy is needed, and by which route, depends on your imaging and your intended treatment and must be decided with your treating team. Ordering and reporting of pancreatic-protocol CT and MRI with MRCP, CA 19-9 and routine bloods, tumour-board review of the pathology, chemotherapy, maintenance and immune-based systemic treatment, neuroendocrine tumour systemic therapy, radiation, chemoradiation and SBRT, genetic counselling, nutrition and pancreatic enzyme (PERT) support, pain, psycho-oncology and survivorship care are delivered by CION. Endoscopic ultrasound with fine-needle aspiration or core biopsy, percutaneous image-guided biopsy, ERCP with sampling and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, peptide receptor radionuclide therapy and all pancreatic surgery are coordinated with specialist gastroenterology, endoscopy, interventional radiology, nuclear medicine and hepatobiliary partner centres and may be billed there.